HIV/AIDS programmes should focus on improved accessBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7266.963/a (Published 14 October 2000) Cite this as: BMJ 2000;321:963
- Alex Manning, general registrar ([email protected])
- Burwell Surgery, Burwell, Cambridgeshire CB5 0AE
EDITOR—GlaxoWellcome's recent move to reduce the cost of antiretroviral drugs in sub-Saharan Africa,1 although to be applauded, is unlikely to have an impact on most of those infected with or affected by HIV/AIDS in sub-Saharan Africa. The cost of monitoring and treating patients with AIDS with antiretrovirals is high; even an antenatal screening programme creates considerable problems, with extra laboratory and counselling services needed and the risk of a hostile community reaction. Maintaining long term prophylaxis …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial